New therapies for chronic hepatitis B

Liver International

Volumn 36, Issue 6, 2016, Pages 775-782

  Bitton Alaluf, Maya ^a   Shlomai, Amir ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Episomal DNA; Integrative therapy; Viral eradication

Indexed keywords

ANTIVIRUS AGENT; RIBONUCLEASE H; RIBONUCLEASE INHIBITOR; TOLL LIKE RECEPTOR AGONIST; VACCINE; CIRCULAR DNA; HEPATITIS B VACCINE; VIRUS DNA;

ADAPTIVE IMMUNITY; CHRONIC HEPATITIS B; CRISPR CAS SYSTEM; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; REVIEW; RNA INTERFERENCE; VIRUS CAPSID; VIRUS INHIBITION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; DNA, CIRCULAR; DNA, VIRAL; DRUG DELIVERY SYSTEMS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, INNATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84960910158     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13086     Document Type: Review

References (82)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
5. Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
6. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34: 1145-58.
7. Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013; 33: 137-50.
8. Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565-81.
9. Wong DKH, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis BA meta-analysis. Ann Intern Med 1993; 119: 312-23.
10. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
11. Marcellin P, Bonino F, Lau GKK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon Alfa-2a. Gastroenterology 2009; 136: 2169-79.e4.
12. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. The Lancet 2005; 365: 123-9.
13. Li G-J, Yu Y-Q, Chen S-L, et al. Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment. Antimicrob Agents Chemother 2015; 59: 4121-8.
14. Gish RG, Given BD, Lai C-L, et al. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res 2015; 121: 47-58.
15. Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013; 98: 27-34.
16. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
17. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
18. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
19. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV Infection. Science 1999; 284: 825-9.
20. Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: a wave of new therapies on the horizon. Antiviral Res 2015; 121: 69-81.
21. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015; 62: 1893-908.
22. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
23. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotech 2003; 21: 639-44.
24. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 2003; 37: 764-70.
25. Shlomai A, Shaul Y. RNA interference - small RNAs effectively fight viral hepatitis. Liver Int 2004; 24: 526-31.
26. Lanford RE, Wooddell CI, Chavez D, et al. ARC-520 RNAi therapeutic reduces hepatitis B virus DNA, S antigen and e antigen in a chimpanzee with a very high viral titer. Hepatology 2013; 58: 707A-07A.
27. Yuen MF, Chan HLY, Given B, et al. Phase II, dose ranging study of ARC-520, a siRNA-based therapeutic, in patients with chronic hepatitis B virus infection. Hepatology 2014; 60: 1280A-80A.
28. Sebestyén M, Wong S, Trubetskoy V, Lewis D, Wooddell C. Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes. Methods Mol Biol. 2015; 1218:163-86.
29. Zlotnick A, Venkatakrishnan B, Tan Z, et al. Core protein: a pleiotropic keystone in the HBV lifecycle. Antiviral Res 2015; 121: 82-93.
30. Deres K, Schröder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-6.
31. Stray SJ, Bourne CR, Punna S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 2005; 102: 8138-43.
32. Klumpp K, Shimada T, Allweiss L, et al. High antiviral activity of the hbv core inhibitor NVR 3-778 in the humanized UPA/SCID mouse model. J Hepatol 2015; 62: S250-S50.
33. Lam A, Espiritu C, Flores O, Hartman G, Klumpp K. Effect of the combination of the hbv core inhibitor NVR 3-778 with nucleoside analogs or other hbv core inhibitors on the inhibition of HBV DNA replication in HepG2.2.15 cells. J Hepatol 2015; 62: S559-S59.
34. Gane EJ, Schwabe C, Walker K, et al. Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor. Hepatology 2014; 60: 1279A-79A.
35. Klumpp K, Lam AM, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein. Proc Natl Acad Sci USA 2015; 112: 15196-201.
36. Tavis JE, Lomonosova E. The hepatitis B virus ribonuclease H as a drug target. Antiviral Res 2015; 118: 132-8.
37. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014; 146: 1070-83.e6.
38. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049.
39. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotech 2008; 26: 335-41.
40. Volz T, Allweiss L, ḾBarek MB, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013; 58: 861-7.
41. Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology 2014; 57: 151-7.
42. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014; 147: 48-64.
43. Bogomolov P, Voronkova N, Allweiss L, et al. A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B. Hepatology 2014; 60: 1279A-80A.
44. Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol 2015; 36: 61-6.
45. Luangsay S, Gruffaz M, Isorce N, et al. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol 2015; 63: 1314-22.
46. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-74.
47. Ferrari C. HBV and the immune response. Liver Int 2015; 35: 121-8.
48. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-64.
49. Sasai M, Yamamoto M. Pathogen recognition receptors: ligands and signaling pathways by toll-like receptors. Int Rev Immunol 2013; 32: 116-33.
50. Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol 2015; 62: 1237-45.
51. Gane EJ, Lim Y-S, Gordon SC, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol 2015; 63: 320-8.
52. Civril F, Deimling T, de Oliveira MCC, et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 2013; 498: 332-7.
53. Guo F, Han Y, Zhao X, et al. Sting agonists induce an innate antiviral immune response against hepatitis B virus. Antimicrob Agents Chemother 2015; 59: 1273-81.
54. McKeage MJ, Fong P, Jeffery M, et al. 5, 6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting Agent. Clin Cancer Res 2006; 12: 1776-84.
55. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008; 99: 2006-12.
56. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71.
57. Moskophidis D, Lechner F, Hengartner H, Zinkernagel RM. MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice. J Immunol 1994; 152: 4976-83.
58. Oxenius A, Zinkernagel RM, Hengartner H. Comparison of Activation versus Induction of Unresponsiveness of Virus-Specific CD4+ and CD8+ T Cells upon Acute versus Persistent Viral Infection. Immunity 1998; 9: 449-57.
59. Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA. Antiviral Res 2015; 123: 193-203.
60. Vandepapelière P, Lau GKK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585-97.
61. Gaggar A, Coeshott C, Apelian D, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine 2014; 32: 4925-31.
62. Lok ASF, Pan CQ, Han S-H B, et al. Safety and efficacy of GS-4774 in patients with chronic hepatitis B on oral antiviral therapy. Hepatology 2015; 62: 1181A-95A.
63. Mancini --BM, Fontaine H, Bréchot C, Pol S, Michel M-L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24: 4482-9.
64. Fontaine H, Kahi S, Chazallon C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial-ANRS HB02 VAC-ADN. Gut 2015; 64: 139-47.
65. Kuchroo VK, Anderson AC, Petrovas C. Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Curr Opin HIV AIDS 2014; 9: 439-45.
66. Maier H, Isogawa M, Freeman GJ, Chisari FV. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007; 178: 2714-20.
67. Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-Specific T-Cell dysfunction in chronic HBV infection. J Virol 2007; 81: 4215-25.
68. Sherman AC, Trehanpati N, Daucher M, et al. Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir. AIDS Res Hum Retroviruses 2013; 29: 665-72.
69. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity In vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014; 10: e1003856.
70. Koniger C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA 2014; 111: E4244-53.
71. Cui X, McAllister R, Boregowda R, et al. Does tyrosyl DNA phosphodiesterase-2 Play a Role in hepatitis B virus genome repair? PLoS ONE 2015; 10: e0128401.
72. Barrangou R, Marraffini LA. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Mol Cell 2014; 54: 234-44.
73. Kennedy EM, Bassit LC, Mueller H, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015; 476: 196-205.
74. Lin S-R, Yang H-C, Kuo Y-T, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol Ther Nucleic Acids 2014; 3: e186.
75. Ramanan V, Shlomai A, Cox DBT, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep 2015; 5: 10833.
76. Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids 2014; 3: e216.
77. Zhen S, Hua L, Liu YH, et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther 2015; 22: 404-12.
78. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186-91.
79. Cai D, Mills C, Yu W, et al. Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. Antimicrob Agents Chemother 2012; 56: 4277-88.
80. Guo H, Jiang D, Zhou T, et al. Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA Formation. J Virol 2007; 81: 12472-84.
81. Hantz O, Parent R, Durantel D, et al. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 2009; 90: 127-35.
82. Lucifora J, Xia Y, Reisinger F, et al. Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science 2014; 343: 1221-8.